We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.37 | -1.14% | 32.07 | 31.41 | 32.40 | 32.23 | 31.77 | 31.77 | 32,298 | 21:31:55 |
From Apr 2019 to Apr 2024
By Olivia Bugault
Merck KGaA said Monday that two of its CRISPR-Cas9-assisted genome-editing patents have been granted in the U.S.
The pharmaceutical company is in talks to license its technology that will support scientists and researchers in the development of therapies for difficult-to-treat diseases, it said. The two patents have been granted for its CRISPR-Cas9 cleavage and integration technology.
"The company has CRISPR patents granted in Australia, Canada, China, Europe, Israel, Singapore and South Korea with related patent filings in Brazil, India and Japan," Merck KGaA said.
CRISPR-Cas 9 is a technology that edit parts of the genome.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
May 11, 2020 09:45 ET (13:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
